Ascendia

  MARKET NEWS

Novadip Reports Promising Interim Results From First-in-Human Proof-of-Concept Trial of New Game Changer in Bone Field
Avacta Expands its Pipeline with Two Novel Assets Developed Using its pre|CISION Platform
Immutep Announces First-in-Human Phase 1 Study of IMP761 Progresses to Dose Escalation Portion of Trial
BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Immune Regulator for Treatment of Acute Respiratory Distress Syndrome
Biognosys Presents Major Innovations Across the Spectrum of Proteomics Research Applications
mRNA Licensing Agreements Surge 800% in Value as Confidence Grows Beyond Vaccines
Cullinan Therapeutics Receives IND Clearance for CLN-978 Administered Subcutaneously in Patients With Moderate-to-Severe Systemic Lupus Erythematosus
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients With Neuropathic Corneal Pain
IgGenix Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating IGNX001 in Peanut Allergy 

  EXPERT CONTENT & RESOURCES

Private: Lonza: Utilizing Analytical Tools & Predictive Models to De-Risk Drug Development

Private: Lonza: Utilizing Analytical Tools & Predictive Models to De-Risk Drug Development

Drug Development & Delivery recently interviewed Josh Marsh, Bioavailability Enhancement and PBPK Lead Scientist at Lonza, to discuss the benefits of predictive tools and Lonza’s approach.

MediWound Ltd.:  Developing a New Class of Biologic Enzymatic Therapeutic  Products to Debride Wounds

MediWound Ltd.:  Developing a New Class of Biologic Enzymatic Therapeutic  Products to Debride Wounds

Drug Development & Delivery recently interviewed Ofer Gonen, Chief Executive Officer of MediWound, to discuss the company’s innovative approach to debridement.

CPHI Annual Report 2024: Drug Delivery Trends & Insights From a Device Perspective

CPHI Annual Report 2024: Drug Delivery Trends & Insights From a Device Perspective

Significant growth in the drug delivery sector is predicted for many areas, with headliners including cell and gene therapies and the GLP-1 blockbusters. Small molecule-based formulations still dominate innovator pipelines, but advanced biologics are also….

BASF Article - Should Developers Choose a Cosmetic or Pharmaceutical-Grade Excipient?

BASF Article - Should Developers Choose a Cosmetic or Pharmaceutical-Grade Excipient?

As regulations continue to change around cosmetic and pharmaceutical-grade excipients, the pharmaceutical industry has choices to make when investing in quality, risk, and public safety.

  FEATURED EDITORIAL

  COMPANY PROFILE

Phosphorex, a leading CDMO located just 26.2 miles from Boston in Hopkinton, MA. Our state-of-the-art facility spans at 30,000 Sq. Ft., with an additional 12,000 Sq. Ft. of cGMP space set to come online in 2025. With our expertise and innovative technologies, we excel in encapsulating drugs into microspheres or nanoparticles, enabling targeted delivery, protection of therapeutic agents, controlled release, and improved bioavailability. From proof-of-concept to clinical studies, our integrated solution supports all phases of formulation development. Click here for more.

  WHITEPAPERS & WEBINARS

Private: WEBINAR - Lipid Nanoparticle (LNP) Characterization: Leveraging HPLC-CAD for Lipid Quantification Assay

Private: WEBINAR - Lipid Nanoparticle (LNP) Characterization: Leveraging HPLC-CAD for Lipid Quantification Assay

Whether you’re involved in research, development, or quality control, this webinar will equip you with the knowledge and tools you need to enhance your analytical processes and ensure success in your LNP projects.

WEBINAR ON DEMAND: Advantages of Carbopol® Polymers in Oral Formulations

WEBINAR ON DEMAND: Advantages of Carbopol® Polymers in Oral Formulations

In this video, the Lubrizol team together with the IMCD US team takes you through formulation aspects of Carbopol® polymers as well as the results of a case study on an Acetaminophen oral suspension formulation.

  WHITEPAPERS & WEBINARS

WHITEPAPER - Efficient Development of Miniature Drug-Loaded Implants

WHITEPAPER - Efficient Development of Miniature Drug-Loaded Implants

Drug-eluting implants offer a unique approach to overcoming challenges associated with traditional drug delivery methods. They can provide sustained, continuous release of a therapeutic at the desired site of action.

Download our latest white paper, jointly authored with MeltPrep, to …

WHITEPAPER - Versatility of Geleol™ Mono- and Diglycerides NF

WHITEPAPER - Versatility of Geleol™ Mono- and Diglycerides NF

By: Jasmine Musakhanian, Senior Scientific Director, Gattefossé

INTRODUCTION

Mono and diglycerides, also known as partial glycerides, are versatile lipid excipients that play a pivotal role in the realization of drug products and nutraceuticals. Some well-known excipients in this category are …

WHITEPAPER - Unlock the Secrets of Spray Drying for Sticky APIs

WHITEPAPER - Unlock the Secrets of Spray Drying for Sticky APIs

It is widely reported that 40% of New Chemical Entities (NCEs) in the pharmaceutical industry are poorly soluble, leading to inadequate bioavailablity. Spray drying is one of the most promising particle engineering technologies used to overcome solubility issues in active …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

October 30 – Formulation Development
November 6 – Drug Delivery